Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Beginning Cash Balance: 2018-2023

Historic Beginning Cash Balance for Autolus Therapeutics (AUTL) over the last 1 years, with Mar 2023 value amounting to $382.8 million.

  • Autolus Therapeutics' Beginning Cash Balance rose 23.20% to $382.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $980.8 million, marking a year-over-year increase of 16.05%. This contributed to the annual value of $316.4 million for FY2021, which is 54.70% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Beginning Cash Balance of $382.8 million as of Q1 2023, which was up 23.20% from $310.7 million recorded in Q1 2022.
  • Autolus Therapeutics' 5-year Beginning Cash Balance high stood at $382.8 million for Q1 2023, and its period low was -$43.3 million during Q3 2021.
  • Over the past 3 years, Autolus Therapeutics' median Beginning Cash Balance value was $320.7 million (recorded in 2021), while the average stood at $245.2 million.
  • Its Beginning Cash Balance has fluctuated over the past 5 years, first dropped by 6.04% in 2022, then grew by 23.20% in 2023.
  • Over the past 3 years, Autolus Therapeutics' Beginning Cash Balance (Quarterly) stood at -$43.3 million in 2021, then decreased by 6.04% to $310.7 million in 2022, then rose by 23.20% to $382.8 million in 2023.
  • Its last three reported values are $382.8 million in Q1 2023, $310.7 million for Q1 2022, and -$43.3 million during Q3 2021.